The Technical Analyst
Insulet Corp [PODD]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Insulet Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.92% $166.25
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 11 641 mill |
| EPS: | 2.93 |
| P/E: | 56.74 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 70.02 mill |
| Avg Daily Volume: | 0.864 mill |
| RATING 2024-04-19 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 56.74 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.26x |
| Company: PE 56.74 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-71.41 (-142.95%) $-237.66 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 159.98 - 172.52 ( +/- 3.77%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-28 | Petrovic Shacey | Buy | 11 609 | Common Stock |
| 2024-02-28 | Petrovic Shacey | Sell | 11 609 | Common Stock |
| 2024-02-28 | Petrovic Shacey | Sell | 11 609 | Employee Stock Option (Right to Buy) |
| 2024-02-27 | Singh Prem | Buy | 2 100 | Common Stock |
| 2024-02-28 | Singh Prem | Sell | 90 | Common Stock |
| INSIDER POWER |
|---|
| 9.84 |
| Last 100 transactions |
| Buy: 218 884 | Sell: 213 172 |
Forecast:
16:00 - $166.06
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $166.06
Forecast 2: 16:00 - $166.06
Forecast 3: 16:00 - $166.06
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $166.25 (0.92% ) |
| Volume | 0.745 mill |
| Avg. Vol. | 0.864 mill |
| % of Avg. Vol | 86.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PODD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $196.43 | N/A | Active |
|---|
PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-03 06:00:00 - Press Release
Nadav Eiron Joins Crusoe As Senior Vice President Of Cloud Engineering
San francisco--(business wire)--crusoe energy systems llc (“crusoe”) announced today that nadav eiron has joined the company as a senior vice president to lead the cloud engineering team in crusoe's san francisco office. eiron will lead crusoe's efforts to scale its cloud platform, purpose-built for artificial intelligence and high-performance computing workloads. with decades of experience at google and ibm, eiron will keep crusoe at the forefront of architecture and usability innovation acros.
2024-04-03 06:00:00 - Press Release
Insulet To Announce First Quarter 2024 Financial Results On May 9, 2024
Acton, mass.--(business wire)--insulet corporation (nasdaq: podd) (insulet or the company), the global leader in tubeless insulin pump technology with its omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2024 on may 9, 2024 after the close of the financial markets. in connection with the release, management will host a conference call that day at 4:30 p.m. (eastern time). the link to the live call will be available on the investor relat.
2024-03-20 06:00:00 - Press Release
Insulet Appoints Ana Maria Chadwick As Chief Financial Officer
Acton, mass.--(business wire)--insulet corporation (nasdaq: podd) (insulet or the company), the global leader in tubeless insulin pump technology with its omnipod® brand of products, today announced that ana maria chadwick has been appointed executive vice president, chief financial officer and treasurer, effective april 22, 2024. today's announcement concludes an extensive search process conducted by the company. “we are thrilled to welcome ana to insulet,” said jim hollingshead, president and.
2024-03-08 06:00:00 - Press Release
Insulet's Randomized Controlled Trial (op5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System Is Superior To Pump Therapy
Acton, mass.--(business wire)--insulet corporation (nasdaq: podd) (insulet or the company), the global leader in tubeless insulin pump technology with its omnipod® brand of products, today presented positive results from its first randomized controlled trial (rct) showing improved glycemic and patient-reported outcomes in type 1 diabetes with the omnipod 5 automated insulin delivery system (omnipod 5). the op5-003 trial results were presented at the 17th international conference on advanced tec.
2024-03-05 06:00:00 - Press Release
Insulet To Present Results From First Omnipod® 5 Randomized Controlled Trial (op5-003) At The 17th International Conference On Advanced Technologies & Treatments For Diabetes (attd)
Acton, mass.--(business wire)--insulet corporation (nasdaq: podd) (insulet or the company), the global leader in tubeless insulin pump technology with its omnipod® brand of products, will present new clinical evidence related to the omnipod 5 automated insulin delivery system (omnipod 5) at the 17th international conference on advanced technologies & treatments for diabetes (attd) taking place march 6 – 9, 2024 in florence, italy, and online. “we are thrilled to unveil the results of our in.
Latest News
2024-04-19 08:50:16 - Zacks Investment Research
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.
2024-04-17 09:51:10 - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
2024-04-15 09:45:30 - InvestorPlace
7 Stable Stocks for 50% Returns by Early 2025
Investors who seek 50% returns in less than 12 months generally will have many choices within stable stocks. The general maxim regarding risk and return applies here: Risky, unstable stocks tend to offer much higher return potential.
2024-04-12 13:16:12 - Zacks Investment Research
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2024-04-02 10:46:07 - Zacks Investment Research
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2024-04-02 09:37:05 - Zacks Investment Research
5 Medical Product Stocks to Buy Amid Industry Challenges
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.
2024-03-28 10:56:03 - Zacks Investment Research
Wall Street Analysts See a 38.87% Upside in Insulet (PODD): Can the Stock Really Move This High?
The consensus price target hints at a 38.9% upside potential for Insulet (PODD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-03-22 13:01:24 - Zacks Investment Research
5 Stocks to Buy on the Dip to Gain From the Wall Street Rally
We have narrowed our search to five large-cap stocks with attractive valuations. These are TWLO, ZS, NEE, AWK and PODD.
2024-03-21 08:00:19 - Zacks Investment Research
3 Strong Stocks Down at Least 30% to Buy Now
Three S&P 500 stocks worth considering as buy-and-hold investments that are down at least 30% from their highs even as the market trades at records.
2024-03-18 09:25:26 - Zacks Investment Research
Here's Why You Should Buy Insulet (PODD) Stock Right Now
Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.